Pharmaceutical filing citing a New England Journal of Medicine paper — Traws Pharma, 2025-06-30
Traws PharmaTraws PharmaNASDAQ TRAW
Filings SEC · Quote Yahoo cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way the paper was written and the scope it actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S. listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Traws Pharma on 2025-06-30 were 7.01 Reg FD disclosure · 8.01 other events · 9.01 financial statements · exhibits. The company cited a paper published in New England Journal of Medicine in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
TRAW information. 2. https://www.nejm.org/doi/full/10.1056/NEJMsb2506929 3. BIKTARVY is a registered trademark o f G ilead Science, Inc. 4.
What the reader should first check is where the company placed the paper in the press release. Next, the reader should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is limited to this.
The paper title is An Evidence-Based Approach to Covid-19 Vaccination and it was published in New England Journal of Medicine on 2025-05-20. The authors are affiliated with the Center for Biologics Evaluation and Research · United States Food and Drug AdministrationFood and Drug Administration
Regulator · Website. The summary at the beginning of the paper is called abstract. This article reads only up to that point. This paragraph was written by a person after filtering a draft written by a machine reading the abstract by numerical comparison, and thus is of a different grade than a full-text reading and original judgment.
This article is a commentary published in the medical journal NEJM, not a research paper. Since the abstract is not publicly available, it has not been summarized. What can be known from the title is that it is an article discussing how to determine the administration of the coronavirus vaccine based on evidence. It is not an article containing new experimental results.
What the abstract does not answer remains in the full text and appendices. This article, which has not gone beyond that, leaves the blanks as they are. The reader should determine for themselves which sentence in the abstract corresponds to the cited passage cited by the company, by comparing the two citations above.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are about a month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −17.0% | The extent of movement before the filing |
| On the day of the filing | +3.0% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +4.3% | One week |
| Cumulative +1~+20 trading days | +0.1% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +0.1% in this case is within the bottom 65% of the 142 samples and is within the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +0.1% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies within or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There are two more cases where the same company wrote papers in 8-K, and they are placed together in the table below.
| Disclosure date | the journal of the paper | a month's excess return |
|---|---|---|
| 2025-05-27 | New England Journal of Medicine | +5.5% |
| 2025-06-03 | British Journal of Dermatology | −27.4% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Here, only the item numbers are listed. In 8-K filings without titles, the item numbers indicate the type of content, so one can determine whether it was an earnings announcement or a contract by the number. The specifics of what occurred are read in the original text of each link.
- 2025-07-03 8-K Item 5.02 — Changes in Directors and Executive Officers
- 2025-08-14 8-K Items 2.02, 7.01, 9.01 — Earnings announcement · Reg FD disclosure · Financial statements · Exhibits
- 2025-08-18 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper re-examined what and showed up to where. How many times the paper cited by the company was cited afterward can be checked again through the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Term Explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission by a U.S.-listed company when it has news to inform shareholders. The type of report is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company itself by removing the portion influenced by the overall market rise or fall.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.